Gilead hepatitis C drug patent faces European challenge
March 27, 2017 at 04:28 AM EDT
LONDON, March 27 (Reuters) - Two international medical humanitarian organisations said on Monday they had challenged the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.
